Clinical trials: Type1 Diabetes
Type 2 Diabetes
Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
This study will evaluate the effects of impaired blood flow regulation on exercise. It will also determine whether the effects are more important in the heart or in the skeletal muscle tissue during exercise.
- Trial name
- InsITE (NCT00786019)
- Testing
- Exercise program, Ascorbic Acid (Vitamin C)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes Mellitus, Hypoglycemia
Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas
This is a randomized crossover trial with 1:1 randomization to the admission sequence of using the Control AP system (rMPC - Naïve Model Predictive Control) vs.
- Trial name
- NCT03859401
- Testing
- EnMPC (Ensemble Model Predictive Control) AP Controller, rMPC (Naïve Model Predictive Control) AP Controller
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Marc Breton
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Hypoglycemia
PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
The purpose of the study is to assess the safety, speed of absorption, and onset of action of G-Pump™ (glucagon infusion) at three subcutaneous doses as compared to Novo GlucaGen®, all delivered via an OmniPod® infusion pump to…
- Trial name
- NCT02081001
- Testing
- Novo Nordisk GlucaGen®, G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Xeris Pharmaceuticals
Recent Onset type1 Diabetes
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients.
- Trial name
- NCT04628481
- Testing
- Ladarixin
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 289 people
- Sponsor
- Dompé Farmaceutici S.p.A
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Type 1 Diabetes
Self-Management in Young Adults With Type 1 Diabetes
Type 1 Diabetes (T1D) affects 1.6 million Americans, and only 14% of young adults age 18-25 years achieve glycemic targets (glycosylated hemoglobin A1C <7.0%).
- Trial name
- SLEEPT1D (NCT04975230)
- Testing
- Sleep Self-Management
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Case Western Reserve University
Type 1 Diabetes, Hypoglycemia
CGM Use in Poorly Controlled Youth With Type 1 Diabetes
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in high risk, poorly controlled pediatric Type 1 diabetes patients increases uptake of personal CGM use, and…
- Conditions
- Type 1 Diabetes, Hypoglycemia, High Blood Sugar
- Trial name
- IMPaCT (NCT04721145)
- Testing
- Dexcom G6 Continuous Glucose Monitor
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
The purpose of the study is to conduct a multicenter, randomized effectiveness trial of The 3Ms. The proposed study will use an effectiveness-implementation "Hybrid 1" design.
- Trial name
- 3Ms (NCT03168867)
- Testing
- The 3Ms Intervention
- Where
- 7 sites in United States
- Volunteers
- 149 people
- Sponsor
- Wayne State University
Type 1 Diabetes Mellitus
Communication and Coping for Mothers of Adolescents With Type 1 Diabetes
Mothers of adolescents with type 1 diabetes experience high levels of depressive symptoms, which impair their ability to monitor and manage diabetes treatment effectively.
- Trial name
- T1D (NCT03818711)
- Testing
- Communication & Coping Intervention, Education & Check Ins
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- Vanderbilt University Medical Center
Type 1 Diabetes, Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
- Trial name
- QWINT-5 (NCT05463744)
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 83 sites in United States, Argentina and 5 more
- Volunteers
- 692 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
Type1 Diabetes Mellitus
The Insulin-Only Bionic Pancreas Bridging Study
The iLet is a closed-loop delivery system that can be used in insulin-only, bihormonal, or glucagon-only configurations. Previous studies have utilized a phone-based bionic pancreas.
- Trial name
- NCT03565666
- Testing
- iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants…
- Trial name
- EDITION IV (NCT01683266)
- Testing
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Where
- 147 sites in United States, Canada and 11 more
- Volunteers
- 549 people
- Sponsor
- Sanofi
Type1 Diabetes Mellitus, Adiposity
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
The purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes.
- Trial name
- T1D (NCT03582956)
- Testing
- Euglycemic hyperinsulinemic clamp with tracer enhancement
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Diabetes Mellitus, Type 1
A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin.
- Trial name
- NCT00575159
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Type 1 Diabetes
Threshold Suspend in Pediatrics at Home
The study objective is to demonstrate that home use of Threshold Suspend (TS) is not associated with glycemic deterioration in pediatric patients with type 1 diabetes, as measured by change in A1C.
- Trial name
- NCT02120794
- Testing
- 530G Insulin pump
- Where
- 16 sites in United States
- Volunteers
- 194 people
- Sponsor
- Medtronic MiniMed, Inc.